The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: Evidence for a novel CCK receptor subtype?

Neuropharmacology

Volumn 36, Issue 11-12, 1997, Pages 1679-1688

  Van Kampen, J ^a   Stoessl, A J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CCK(B) receptor; Cholecystokinin (CCK); Dopamine; Dopamine D1 receptor; Grooming (rat)

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; DIAZEPAM; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; GROOMING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; RAT; SNIFFING;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BEHAVIOR, ANIMAL; BENZODIAZEPINONES; CHOLECYSTOKININ; DEVAZEPIDE; DIAZEPAM; DOPAMINE AGONISTS; GABA MODULATORS; GROOMING; HORMONE ANTAGONISTS; MALE; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, DOPAMINE D1;

EID: 0031407027     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00168-8     Document Type: Article

References (65)

1. Altar C. A., Boyar W. C., Oei E. and Wood P. L. (1988) Cholecystokinin attenuates basal and drug-induced increases of limbic and striatal dopamine release. Brain Research 460: 76-82.
2. 3H] L-364,718 membrane binding assays. Molecular Pharmacology 36: 285-290.
3. Bluinstein L. K., Crawley J. N., Davis L. G. and Baldino F. Jr. (1987) Neuropeptide modulation of apomorphine-induced stereotyped behavior. Brain Research 404: 293-300.
4. Chang R. S. L. and Lotti V. J. (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proceedings of the National Academy of Sciences U.S.A. 83: 4923-4930.
5. Cohen S. L., Knight M., Tamminga C. A. and Chase T. N. (1982) Cholecystokinin-octapeptide effects on conditioned-avoidance behaviour, stereotypy and catalepsy. European Journal of Pharmacology 83: 213-222.
6. Crawley J. N., Hays S. E., Paul S. M. and Goodwin F. K. (1981) Cholecystokinin reduces exploratory behaviour in mice. Physiology and Behavior 27: 407-411.
7. Crawley J. N., Stivers J. A., Bluinstein L. K. and Paul S. M. (1985) Cholecystokinin potentiates dopamine-mediated behaviours: evidence for modulation specific to site of coexistence. Journal of Neuroscience 5: 1972-1983.
8. Crawley J. N. (1992) Subtype-selective cholecystokinin receptor antagonists block cholecystkinin modulation of dopamine-mediated behaviours in the rat mesolimbic pathway. Journal of Neuroscience 12: 3380-3391.
9. A receptors of the postero-median part of the nucleus accumbens. Pharmacology, Biochemistry and Behavior 34: 157-163.
10. De Montigny C. (1989) Cholecystokinin-tetrapeptide induces panic attack in patients with panic disorder. Canadian Journal of Psychiatry 35: 83-85.
11. Derrien M., McCort-Tranchepain I., Ducos B., Roques B. P. and Durieux C. (1994) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacology, Biochemistry and Behavior 49: 133-141.
12. De Witte Ph., Heidbreder C., Roques B. and Vanderhaeghen J. J. (1987) Opposite effects of cholecystokinin octapeptide and tetrapeptide depending on the site of administration into the nucleus accumbens. Neurochemistry International 4: 473-479.
13. Dourish C. T., Hawley D. and Iversen S. D. (1988) Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. European Journal of Pharmacology 147: 469-472.
14. 1 dopamine receptors. In Multiple Cholecystokinin Receptors in the CNS. ed. C. T. Dourish, S. J. Cooper, S. D. Iversen and L. L. Iversen, pp. 417-425. Oxford University Press, Oxford.
15. Freeman A. S. and Chiodo L. A. (1988) Electrophysiological effects of cholecystokinin octapeptide on identified rat nigrostriatal dopaminergic neurons. Brain Research 439: 266-274.
16. 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiologica Scandinavica 113: 567-569.
17. Glenthoj B., Hemmingsen R., Allerup P. and Bolwig T. G. (1990) Intermittent versus continuous neuroleptic treatment in a rat model. European Journal of Pharmacology 190: 275-286.
18. A receptor antagonist, L-364,718 (devazepide). Psychopharmacology 101: 384-389.
19. B receptors mediate the regulation of exploratory behaviour in the rat. European Journal of Pharmacology 193: 379-381.
20. Hill D. R., Campbell N. J., Shaw T. M. and Woodruff G. N. (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. Journal of Neuroscience 7: 2967-2976.
21. 3H-devazepide. Journal of Neuroscience 10: 1070-1081.
22. Hill D. R. and Woodruff G. N. (1990) Differentiation of central chclecystokinin receptor binding sites using the non-peptide antagonists devazepide and L-365,260. Brain Rent-arch 526: 276-283.
23. Hill. D. R., Singh, L., Boden, P., Pinnock, R., Woodruff, G. N. and Hughes, J. (1992) Detection of CCK receptor subtypes in mammalian brain using highly selective non-peptide antagonists. In Multiple Cholecystokinin Receptors in the CNS, ed. C. T. Dourish, S. J. Cooper, S. D. Iversen and L. L. Iversen, pp. 57-76. Oxford University Press, Oxford.
24. Hommer D. W. and Skirboll L. (1983) Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. European Journal of Pharmacology 91: 151-152.
25. Jagerschmidt A., Popovici T., O'Donohue M. and Roques B. P. (1994) Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. Journal of Neurochemistry 63: 1199-1206.
26. Kiharu T., Ikeda M., Matsubara K. and Matsushita A. (1993) Differential effects of ceruletide on amphetamine-induced behaviours and regional dopamine release in the rat. European Journal of Pharmacology 230: 271-277.
27. 26-33): evidence for CCK-B receptor heterogeneity. Journal of Pharmacology and Experimental Therapeutics 255: 1278-1286.
28. Léna I., Daugé V., Roques B. P. and Durieux C. (1996) Distinct pharmacological profiles of two CCK-B agonists: further evidence of rat CCK-B receptor subsites. Society for Neuroscience Abstracts 22: 78.
29. Levy A. D., See R. E., Levin E. D. and Ellison G. D. (1987) Neuroleptic-induced oral movements in rats: methodological issues. Life Sciences 41: 1499-1506.
30. Mansbach R. S. and Lorenz D. N. (1983) Cholecystokinin (CCK-8) elicits prandial sleep in rats. Physiology and Behavior 30: 179-185.
31. Markstein R. and Hökfelt T. (1984) Effect of cholecystokinin-octapeptide on dopamine release from slices of cat caudate nucleus. Journal of Neuroscience 4: 570-575.
32. Marshall F. H., Barnes S., Hughes J. and Woodruff G. N. (1991) Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. Journal of Neurochemistry 56: 917-922.
33. Matsubara K. and Matsushita A. (1984) Long-lasting reduction of amphetamine-induced hyperactivity in rats after combined administration of caerulein with haloperidol. European Journal of Pharmacology 101: 157-158.
34. Moran T. H., Robinson P. H., Goldrich M. S. and McHugh P. R. (1986) Two brain cholecystokinin receptors: implications for behavioural actions. Brain Research 362: 175-179.
35. Moroji T. and Hagino Y. (1986) A behavioural pharmacological study on CCK-8 related peptides in mice. Neuropeptides 8: 273-286.
36. 3H]dopamine binding by cholecystokinin octapeptide (CCK-8). Peptides 3: 539-543.
37. Oldendorf W. H. (1981) Blood-brain barrier permeability to peptides: pitfalls in measurement. Peptides 2 (Suppl. 2): 109-111.
38. O'Neill M. F., Kawamura S. and Dourish C. T. (1992) Behavioural analysis of the effects of CCK agonists and antagonists on opiod analgesia. Neuroscience letters 42 (Suppl.): S59.
39. Plappert C. F., Pilz P. K. and Schnitzler H. V. (1993) Acoustic startle response and habituation in freezing and nonfreezing rats. Behavioral Neuroscience 107: 981-987.
40. Ravard S. and Dourish C. T. (1990) Cholecystokinin and anxiety. Trends in Pharmacological Sciences 11: 271-273.
41. Rehfeld, J. F. (1992) CCK and anxiety: introduclion. In Multiple Cholecystokinin Receptors in the CNS, ed. C. T. Dourish, S. J. Cooper, S. D. Iversen and L. L. Iversen, pp. 117-120. Oxford University Press, Oxford.
42. Rex A., Barth T., Voigt J. P., Domeney A. M. and Fink H. (1994) Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Neuroscience Letters 172: 139-142.
43. Roth K. A. and Katz R. J. (1979) Stress, behavioural arousal and open field activity - a reexamination of emotionality in the rat. Neuroscience and Biobehavioral Reviews 3: 247-263.
44. Rovati, L. C. and Makovec, F. (1988) New pentanoic acid derivatives with potent CCK antagonistic properties: different activity on the periphery vs. central nervous system. In Cholecystokinin Antagonists, ed. R. Y. Wang and R. Schoenfeld, pp. 1-11. Alan R. Liss, New York.
45. Ruggeri M., Ungerstedt U., Agnati L. F., Mutt V., Härfstrand A. and Fuxe K. (1987) Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anaesthetized rat. Neurochemistry International 10: 509-520.
46. Savasta M., Ruberte E., Palacios J. M. and Mengod G. (1989) The colocalization of cholecysokinin and tyrosine hydroxylase mRNA in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridization. Neuroscience 29: 363-369.
47. Seroogy K. B., Schalling M., Brené S., Dagerlind Å., Chai S. Y. Hökfelt T., Persson H., Brownstein M., Huan R., Dixon J., Filer D., Schlessinger D. and Goldstein M. (1989) Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studied using in situ hybridization combined with immunohistochemistry. Experimental Brain Research 74: 149-162.
48. Skirboll L. R., Grace A. A., Hommer D. W., Rehfeld J., Goldstein M., Hökfelt T. and Bunney B. S. (1981) Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6: 2111-2124.
49. Snyder G. L., Fisone G., Morino P., Gundersen V., Ottersen O. P., Hökfelt T. and Greengard P. (1993) Regulation by the neuropeptide Cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatum. Proceedings of the National Academy of Sciences U.S.A. 90: 11277-11281.
50. Stoessl A. J., Dourish C. T. and Iversen S. D. (1987) Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. Psychopharmacology 93: 336-341.
51. Studier J. M., Reibaud M., Herve D., Blanc G., Glowinski J. and Tassin J. P. (1986) Opposite effects of sulfated cholecystokinin on DA-sensitive adenylate cyclase in two areas of the rat nucleus accumbens. European Journal of Pharmacology 126: 125-128.
52. Vaccarino F. J. and Koob G. F. (1984) Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward. Neuroscience Letters 52: 61-66.
53. Vaccarino F. J. and Rankin J. (1989) Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behavioral Neuroscience 103: 831-836.
54. Vanderhaeghen, J. J. and Schiffmann, S. N. (1992) Distribution of brain neuronal CCK. An in situ hybridization study. In Multiple Cholecystokinin Receptors in the CNS, ed. C. T. Dourish, S. J. Cooper, S. D. Iversen and L. L. Iversen, pp. 38-56. Oxford University Press, Oxford.
55. 8 as radioligand. Journal of Neuroscience 4: 1021-1033.
56. Van Erp A. M. M., Kruk M. R., Meelis W. and Willekens-Bramer D. C. (1994) Effect of environmental Stressors on time course, variability and form of self-grooming in the rat: handling, social contact, defeat, novelty, restraint and fur moistening. Behavioural Brain Research 65: 47-55.
57. Van Kampen J. M. and Stoessl A. J. (1995) Cholecystokinin attenuates grooming via an atypical receptor type. Neuroscience Abstracts 21: 2094.
58. 1 receptor interactions in the rat. European Journal of Pharmacology 298: 1-15.
59. Van Ree J. M., Gaffori O. and De Wied D. (1983) In rats, the behavioural profile of CCK-8 related peptides resembles that of antipsychotic agents. European Journal of Pharmacology 93: 63-78.
60. Wank S. A., Harkins R., Jensen R. T., Shapira H., de Weerth A. and Slattery T. (1992a) Purification, molecular cloning, functional expression of the cholecystokinin receptor from rat pancreas. Proceedings of the National Academy of Sciences U.S.A. 89: 3125-3129.
61. Wank S. A., Pisegna J. R. and de Weerth A. (1992b) Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proceedings of the National Academy of Sciences U.S.A. 89: 8691-8695.
62. Wank S. A., Pisegna J. R. and de Weerth A. (1994) Cholecystokinin receptor family: molecular cloning, structure, and functional expression in rat, guinea pig, and human. Annals of the New York Academy of Sciences 713: 49-66.
63. Weiss F., Tanzer D. J. and Ettenberg A. (1988) Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats. Pharmacology, Biochemistry and Behavior 30: 309-317.
64. 2+ release. Neuroscience Letters 175: 95-98.
65. Yim C. C. and Mogenson G. J. (1991) Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens. Brain Research 541: 12-20.